首页>
外国专利>
Peptide-inhibitor TGF-β1 and a cyclodextrin or a derivative thereof, emulsions Peptide inhibitors of TGF-β1, PHARMACEUTICALS ON THEIR BASE, METHODS FOR THE ABOVE SET and emulsions, products obtained by the aforementioned method, and methods of treating diseases and / or conditions mediated by TGF-β1
Peptide-inhibitor TGF-β1 and a cyclodextrin or a derivative thereof, emulsions Peptide inhibitors of TGF-β1, PHARMACEUTICALS ON THEIR BASE, METHODS FOR THE ABOVE SET and emulsions, products obtained by the aforementioned method, and methods of treating diseases and / or conditions mediated by TGF-β1
1. The complex of the peptide inhibitor of TGF-β1 and cyclodextrin or its derivative, consisting of a peptide that inhibits TGF-β1, the sequence of which is at least 70% identical to one of the amino acid sequences of SEQ ID NO: 1-23, or its salts , functional derivatives, variants, analogues or fragments thereof with the ability to inhibit TGF-β1 and cyclodextrin selected from the group of cyclodextrins, including β-cyclodextrin and γ-cyclodextrin. 2. The complex according to claim 1, wherein the β-cyclodextrin is selected from the group of β-cyclodextrins, including mono (C-C) hydroxyalkylated β-cyclodextrin and poly (C-C) hydroxyalkylated β-cyclodextrin. The complex according to claim 1 or 2, which contains a peptide that inhibits TGF-β1, in a mass ratio of from about 0.002: 1 to about 0.024: 1 relative to cyclodextrin. A pharmaceutical preparation comprising the complex according to any one of claims 1 to 3, wherein the TGF-β1 inhibiting peptide is present in a therapeutically effective amount and the cyclodextrin is a pharmaceutically acceptable cyclodextrin. 5. The drug according to claim 4, which further comprises cetyl PEG / PPG-10/1 dimethicone. TGF-β1 inhibitor peptide emulsion comprising cetyl PEG / PPG-10/1 dimethicone. 7. The emulsion according to claim 6, in which the sequence of the peptide inhibiting TGF-β1 is at least 70% identical to one of the amino acid sequences of SEQ ID NO: 1-23.8. The emulsion according to claim 7, in which the peptide inhibiting TGF-β1 forms a complex with cyclodextrin or its derivative. The emulsion of claim 8, wherein the TGF-β1 inhibiting peptide is present in a weight ratio of from about 0.002: 1 to about 0.024: 1 relative to cyclodextrin. Pharmaceutical
展开▼
